Before the French biotechnology company $Abivax S.A. (ABVX.US)$ announced the data for its core drug obefazimod, investment bank Guggenheim raised the company's target price from 150 US dollars to 175 US dollars and assigned a "Buy" rating. $Abivax S.A. (ABVX.US)$ The stock rose more than 5% in pre-market trading.
Analyst Yatin Suneja stated that this adjustment was based on an optimistic outlook for the Week 44 maintenance period data readout (to be announced soon) of its core drug obefazimod.
On December 15, Abivax announced its third-quarter financial results for 2025. The company reported revenue of $2.4 million, surpassing market expectations by $1.06 million. However, the net loss per share for the quarter totaled $1.68. The company's net loss for the first nine months expanded to €254.1 million, up from €136.9 million in the same period in 2024. Its financial activities reflect a stronger focus on its lead drug candidate, obefazimod, a first-in-class oral miR-124 enhancer.
Research and development expenses increased to €133.4 million, primarily driven by progress in the ABTECT Phase III project for ulcerative colitis and the ENHANCE-CD Phase IIb trial for Crohn's disease. Abivax is preparing for several key milestones in 2026. The primary results of the ABTECT maintenance trial are expected to be announced in the second quarter of 2026, which will provide the final clinical basis for the planned submission of a New Drug Application to the U.S. FDA in the second half of 2026.
Editor/Doris